RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Phathom Pharmaceuticals Stock

Phathom Pharmaceuticals ROCE 2024

Phathom Pharmaceuticals ROCE

2.3

Ticker

PHAT

ISIN

US71722W1071

WKN

A2PT0F

In 2024, Phathom Pharmaceuticals's return on capital employed (ROCE) was 2.3, a -0.25% increase from the 2.31 ROCE in the previous year.

Phathom Pharmaceuticals Aktienanalyse

What does Phathom Pharmaceuticals do?

Phathom Pharmaceuticals Inc. is a pharmaceutical company specializing in the development and marketing of medications for the treatment of gastrointestinal disorders. The company is headquartered in Florham Park, New Jersey and was founded in 2016. The company's business model is focused on utilizing its innovative technology and expertise in the medical treatment of gastrointestinal disorders to improve the lives of patients. It works closely with doctors and hospitals to ensure that its products are developed to the highest standards. The company is divided into different business segments to enable optimal patient care and market penetration. The key business segments are: 1. Gastroesophageal reflux disease Phathom has developed a medication called Vonoprazan for the treatment of gastroesophageal reflux disease. This common condition occurs when stomach acid flows back into the esophagus, causing pain, inflammation, and heartburn. The medication blocks the production of stomach acid, thus helping to relieve the symptoms of reflux disease. 2. Helicobacter pylori infection The company has also developed a medication called Ryzodeg for the treatment of Helicobacter pylori infection. This infection, caused by a type of bacteria, can lead to stomach ulcers and other gastrointestinal disorders. Ryzodeg is a combination of an antimicrobial substance and a proton pump inhibitor, which together are more effective than individual medications. 3. Eosinophilic esophagitis Phathom is currently developing a medication for the treatment of eosinophilic esophagitis (EoE), an allergic inflammation of the esophagus that can cause difficulty swallowing, pain, and diarrhea. The medication is currently in the clinical development phase and could soon be on the market. Phathom Pharmaceuticals was founded by a group of experienced executives from the pharmaceutical and biotech industry, including CEO Dr. Azmi Nabulsi and COO Dr. Tuan Ha-Ngoc. Both have extensive experience in the development and marketing of medications and contribute their expertise to the company's management. The company also specializes in partnerships with other pharmaceutical companies and clinical research institutions to advance its research and development. For example, the company has entered into a strategic partnership with Takeda Pharmaceuticals to advance the development and marketing of Vonoprazan. Phathom Pharmaceuticals is a promising company specializing in the development and marketing of medications for the treatment of gastrointestinal disorders. With its innovative technology and experienced management, the company is expected to continue growing in the future and help improve the health of patients around the world. Phathom Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROCE Details

Unraveling Phathom Pharmaceuticals's Return on Capital Employed (ROCE)

Phathom Pharmaceuticals's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Phathom Pharmaceuticals's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Phathom Pharmaceuticals's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Phathom Pharmaceuticals’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Phathom Pharmaceuticals stock

What is the ROCE (Return on Capital Employed) of Phathom Pharmaceuticals this year?

The ROCE of Phathom Pharmaceuticals is 2.3 undefined this year.

How has the ROCE (Return on Capital Employed) of Phathom Pharmaceuticals developed compared to the previous year?

The ROCE of Phathom Pharmaceuticals has increased by -0.25% decreased compared to the previous year.

What does a high ROCE (Return on Capital Employed) mean for investors of Phathom Pharmaceuticals?

A high Return on Capital Employed (ROCE) indicates that Phathom Pharmaceuticals has efficient capital utilization and is able to achieve a higher return on its invested capital. This can be appealing to investors.

What does a low ROCE (Return on Capital Employed) mean for investors of Phathom Pharmaceuticals?

A low ROCE (Return on Capital Employed) can indicate that Phathom Pharmaceuticals has an inefficient utilization of its capital and may have difficulty in achieving a satisfactory return on its invested capital. This can be uncertain or unattractive for investors.

How does an increase in ROCE from Phathom Pharmaceuticals impact the company?

An increase in the ROCE of Phathom Pharmaceuticals can be an indicator of improved company efficiency and show that it is achieving higher profits in relation to its investments.

How does a reduction in the ROCE of Phathom Pharmaceuticals affect the company?

A decrease in ROCE of Phathom Pharmaceuticals can be an indicator of deteriorated efficiency of the company, indicating that it is generating lower profits in relation to its investments.

What are some factors that can influence the ROCE of Phathom Pharmaceuticals?

Some factors that can affect Phathom Pharmaceuticals's ROCE include efficiency in managing assets, profitability of investments, cost efficiency, and market conditions.

Why is the ROCE of Phathom Pharmaceuticals so important for investors?

The ROCE of Phathom Pharmaceuticals is important for investors as it is an indicator of the company's efficiency and shows how successful the company is in relation to its investments. A high ROCE can indicate strong financial performance of the company.

What strategic measures can Phathom Pharmaceuticals take to improve the ROCE?

To improve the ROCE, Phathom Pharmaceuticals can take measures such as increasing efficiency in asset management, optimizing investments, cost savings, and exploring new revenue sources. It is important for the company to conduct a thorough review of its operations to determine the best strategic actions to improve the ROCE.

How much dividend does Phathom Pharmaceuticals pay?

Over the past 12 months, Phathom Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Phathom Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Phathom Pharmaceuticals?

The current dividend yield of Phathom Pharmaceuticals is .

When does Phathom Pharmaceuticals pay dividends?

Phathom Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Phathom Pharmaceuticals?

Phathom Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Phathom Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Phathom Pharmaceuticals located?

Phathom Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Phathom Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Phathom Pharmaceuticals from 9/8/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/8/2024.

When did Phathom Pharmaceuticals pay the last dividend?

The last dividend was paid out on 9/8/2024.

What was the dividend of Phathom Pharmaceuticals in the year 2023?

In the year 2023, Phathom Pharmaceuticals distributed 0 USD as dividends.

In which currency does Phathom Pharmaceuticals pay out the dividend?

The dividends of Phathom Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Phathom Pharmaceuticals

Our stock analysis for Phathom Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Phathom Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.